Jeffrey Black is recorded as CFO at Exagen Inc. (XGN) and CFO at Boston Scientific Corp (BSX). The newest filing on record that lists Jeffrey Black as CFO at Exagen Inc. (XGN) is dated April 27, 2026. Jeffrey Black was last confirmed as CFO at Standard Biotools Inc. (LAB) in a filing dated April 30, 2025. Earlier roles on record: CFO at Standard Biotools Inc. (LAB) until August 31, 2024 and CFO at Alphatec Holdings, Inc. (ATEC) until April 18, 2021. Exagen Inc. reported in an 8-K filed August 2, 2024 that Jeffrey Black was appointed Chief Financial Officer and principal financial officer for SEC reporting purposes, effective September 1, 2024. Standard Biotools Inc. reported in an 8-K filed July 31, 2024 that Jeffrey Black resigned as Senior Vice President and Chief Financial Officer, effective August 31, 2024. Standard Biotools Inc. reported in an 8-K filed May 15, 2023 that Jeffrey Black was appointed Senior Vice President and Chief Financial Officer, effective May 15, 2023. The proxy statement of Exagen Inc. reports total compensation of $746,190 for Jeffrey Black in fiscal 2025, including a base salary of $465,000. Disclosed compensation is on record for 6 fiscal years. Jeffrey Black has spoken on 6 earnings calls across 3 companies, most recently for Exagen Inc. on August 4, 2026. Those appearances were for Exagen Inc. (XGN), Standard Biotools Inc. (LAB) and Alphatec Holdings, Inc. (ATEC). Exagen Inc. is classified in the Diagnostics & Research industry within the Healthcare sector. Boston Scientific Corp is classified in the Medical Devices industry within the Healthcare sector. Other companies whose calls Jeffrey Black spoke on are classified in the Healthcare sector. Other leadership on record at Exagen Inc. includes John Aballi (CEO, CFO and Board Member), Tina S. Nova (Chairman), Mark Hazeltine (COO) and 6 others.
“On July 25, 2024, Exagen Inc. (the “Company”) appointed, effective as of September 1, 2024, Jeffrey Black to serve as the Company’s Chief Financial Officer and principal financial officer for SEC reporting purposes.”
Exagen Inc. Form 8-K, filed August 2, 2024
· Read the filing
“On July 26, 2024, Jeffrey Black resigned as the Senior Vice President and Chief Financial Officer (serving as the principal financial and accounting officer) of Standard BioTools Inc. (the "Company"), effective as of August 31, 2024.”
Standard Biotools Inc. Form 8-K, filed July 31, 2024
· Read the filing
Jeffrey Black on recent calls
“As John just highlighted, our second quarter results reflect another strong quarter of execution across the business. We achieve record top-line performance, driven by record testing volume in trailing 12-month ASP, and a record contribution from our pharma services offering.”
“As John mentioned, we delivered another strong quarter, highlighted by our third consecutive quarter of volume growth, continued ASP expansion and a balance sheet that we expect secures our runway to positive free cash flow.”
“As John mentioned, we delivered another record revenue quarter. It was also a busy quarter as we executed on initiatives to shore up the balance sheet. As we discussed during the last earnings call, we refinanced our debt and added additional tranches that we can utilize at our option.”
“As a reminder, our first-quarter results on an as-reported basis include the combined operations of Standard BioTools and SomaLogic since the close of the merger on January 5 of this year, while the first quarter of 2023 as reported includes the financial results of the Standard BioTools legacy business only.”
Chief Financial Officer and Corporate Secretary Amounts represent the aggregate grant date fair value of restricted stock unit awards granted to the NEO in the applicable year, as computed in accordance with ASC Topic 718, Compensation-Stock Compensation, rather than the amounts paid to or realized by the NEO. For a discussion of valuation assumptions used in the calculations, see Note 2 and Note 9 to our audited financial statements in our 2025 Annual Report. Amounts reflect the aggregate grant date fair value of stock options granted in 2025 as computed in accordance with ASC Topic 718, Compensation-Stock Compensation. These amounts do not reflect the actual economic value that will be realized by the NEO upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options. The assumptions that we used to calculate these amounts are discussed in Note 2 and Note 9 to our audited financial statements in our 2025 Annual Report. Amounts for 2025 and 2024 represent the non-discretionary portion of cash bonuses paid in March 2026 and March 2025 with respect to corporate performance in 2025 and 2024, respectively, under the bonus plan. For additional information, see "Cash Bonuses" below. Amounts for 2025 and 2024 represent employer matching contributions under our 401(k) plan on behalf of each NEO. Mr. Aballi was appointed as Interim Chief Financial Officer in July 2024 and resigned as Interim Chief Financial Officer in September 2024. Mr. Aballi did not receive additional compensation for the time he served as Interim Chief Financial Officer. Mr. Black was appointed as the Company’s Chief Financial Officer and Corporate Secretary in September 2024.
